0 CHECKOUT

Cervical Dysplasia - Pipeline Review, H1 2015

  • ID: 3275721
  • May 2015
  • 56 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • CEL-SCI Corporation
  • Helix BioPharma Corp.
  • Vaccibody AS
  • MORE

Cervical Dysplasia - Pipeline Review, H1 2015

Summary

The‘Cervical Dysplasia - Pipeline Review, H1 2015’, provides an overview of the Cervical Dysplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Dysplasia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CEL-SCI Corporation
  • Helix BioPharma Corp.
  • Vaccibody AS
  • MORE

List of Tables

List of Figures

Introduction

Report Coverage

Cervical Dysplasia Overview

Therapeutics Development

Pipeline Products for Cervical Dysplasia - Overview

Pipeline Products for Cervical Dysplasia - Comparative Analysis

Cervical Dysplasia - Therapeutics under Development by Companies

Cervical Dysplasia - Therapeutics under Investigation by Universities/Institutes

Cervical Dysplasia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Cervical Dysplasia - Products under Development by Companies

Cervical Dysplasia - Products under Investigation by Universities/Institutes

Cervical Dysplasia - Companies Involved in Therapeutics Development

CEL-SCI Corporation

Helix BioPharma Corp.

Inovio Pharmaceuticals, Inc.

PDS Biotechnology Corporation

Vaccibody AS

Cervical Dysplasia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CIGB-228 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alpha-2b (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Leukocyte Interleukin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PDS-0101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VB-1016 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VGX-3100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cervical Dysplasia - Recent Pipeline Updates

Cervical Dysplasia - Dormant Projects

Cervical Dysplasia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Cervical Dysplasia, H1 2015

Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Investigation by Universities/Institutes, H1 2015

Cervical Dysplasia - Pipeline by CEL-SCI Corporation, H1 2015

Cervical Dysplasia - Pipeline by Helix BioPharma Corp., H1 2015

Cervical Dysplasia - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015

Cervical Dysplasia - Pipeline by PDS Biotechnology Corporation, H1 2015

Cervical Dysplasia - Pipeline by Vaccibody AS, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Cervical Dysplasia Therapeutics - Recent Pipeline Updates, H1 2015

Cervical Dysplasia - Dormant Projects, H1 2015

Cervical Dysplasia - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Cervical Dysplasia, H1 2015

Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- CEL-SCI Corporation
- Helix BioPharma Corp.
- Inovio Pharmaceuticals, Inc.
- PDS Biotechnology Corporation
- Vaccibody AS

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA